239 related articles for article (PubMed ID: 26681196)
1. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.
Ock CY; Nam AR; Lee J; Bang JH; Lee KH; Han SW; Kim TY; Im SA; Kim TY; Bang YJ; Oh DY
Gastric Cancer; 2017 Mar; 20(2):254-262. PubMed ID: 27147244
[TBL] [Abstract][Full Text] [Related]
3. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
5. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
Byers LA; Holsinger FC; Kies MS; William WN; El-Naggar AK; Lee JJ; Hu J; Lopez A; Tran HT; Yan S; Du Z; Ang KK; Glisson BS; Raso MG; Wistuba II; Myers JN; Hong WK; Papadimitrakopoulou V; Lippman SM; Heymach JV
Mol Cancer Ther; 2010 Jun; 9(6):1755-63. PubMed ID: 20530716
[TBL] [Abstract][Full Text] [Related]
6. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.
Bai L; Wang F; Zhang DS; Li C; Jin Y; Wang DS; Chen DL; Qiu MZ; Luo HY; Wang ZQ; Li YH; Wang FH; Xu RH
Sci Rep; 2015 Dec; 5():17717. PubMed ID: 26620439
[TBL] [Abstract][Full Text] [Related]
7. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Zurita AJ; Jonasch E; Wang X; Khajavi M; Yan S; Du DZ; Xu L; Herynk MH; McKee KS; Tran HT; Logothetis CJ; Tannir NM; Heymach JV
Ann Oncol; 2012 Jan; 23(1):46-52. PubMed ID: 21464158
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.
Montero AJ; Diaz-Montero CM; Millikan RE; Liu J; Do KA; Hodges S; Jonasch E; McIntyre BW; Hwu P; Tannir N
Ann Oncol; 2009 Oct; 20(10):1682-7. PubMed ID: 19541791
[TBL] [Abstract][Full Text] [Related]
10. TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer.
Fujii S; Fujihara A; Natori K; Abe A; Kuboki Y; Higuchi Y; Aizawa M; Kuwata T; Kinoshita T; Yasui W; Ochiai A
Cancer Med; 2015 Nov; 4(11):1667-78. PubMed ID: 26336878
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
12. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
13. The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.
Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
Am J Cancer Res; 2015; 5(11):3376-88. PubMed ID: 26807318
[TBL] [Abstract][Full Text] [Related]
14. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan EO; Lin HY; Kim ES; Yan S; Du DZ; McKee KS; Tran HT; Lee JJ; Ryan AJ; Langmuir P; Johnson BE; Heymach JV
J Clin Oncol; 2010 Jan; 28(2):193-201. PubMed ID: 19949019
[TBL] [Abstract][Full Text] [Related]
15. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer.
Takahashi N; Iwasa S; Sasaki Y; Shoji H; Honma Y; Takashima A; Okita NT; Kato K; Hamaguchi T; Yamada Y
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1727-38. PubMed ID: 27256004
[TBL] [Abstract][Full Text] [Related]
17. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancer.
Takahashi N; Furuta K; Taniguchi H; Sasaki Y; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Hamaguchi T; Shimada Y; Yamada Y
Oncotarget; 2016 Jan; 7(4):4925-38. PubMed ID: 26716644
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients.
Seo HY; Park JM; Park KH; Kim SJ; Oh SC; Kim BS; Kim YH; Kim JS
Jpn J Clin Oncol; 2010 Dec; 40(12):1147-53. PubMed ID: 20647232
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma.
Postlewait LM; Squires MH; Kooby DA; Poultsides GA; Weber SM; Bloomston M; Fields RC; Pawlik TM; Votanopoulos KI; Schmidt CR; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Swords D; Jin LX; Cho CS; Winslow ER; Cardona K; Staley CA; Maithel SK
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S832-9. PubMed ID: 26156656
[TBL] [Abstract][Full Text] [Related]
20. Preoperative Plasma Fibrinogen and Serum Albumin Score Is an Independent Prognostic Factor for Resectable Stage II-III Gastric Cancer.
Wu M; Pan Y; Jia Z; Wang Y; Yang N; Mu J; Zhou T; Guo Y; Jiang J; Cao X
Dis Markers; 2019; 2019():9060845. PubMed ID: 31781312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
